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SELECTION OF THE MONTH 
Big Title: A fatty liver leads to a broken heart 
 
Small titles: 
NGAL: A novel biomarker for ACLF 
Deferring treatment increase HCV-associated mortality 
 
FIBROSIS 
In vivo monitoring of hepatic myofibroblasts 
In vivo assessment of hepatic myofibroblasts would be useful for the diagnosis of 
fibrosis and evaluating the effects of anti-fibrotic therapies. Oakley et al. fluorescently 
labelled a single chain antibody (C1-3) that is known to bind hepatic myofibroblasts to 
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monitor fibrogenesis in vivo. They found that IVIS detection of fluorescently labelled-
C1-3 but not a control antibody discriminates between fibrotic and non-fibrotic liver in 
acute and chronic liver fibrosis models. These findings reveal a novel approach in 
the in vivo monitoring of pro-fibrotic cells. 
 
LIVER PROTECTION DEVICE 
Gene- and cell-based therapy 
Liver injuries result in decreased clearance bile acids and their subsequent spill over 
into the peripheral circulation where they can activate the G-protein coupled bile acid 
receptor 1 (also known as GPCR19 or BG37 and is encoded by TGR5). Engagement 
of GPCR19 initiates a variety of processes that are protective for the liver. Bai et al. 
developed a GPCR19-expressing liver-protection device that detected pathologic 
serum bile acid levels and produced therapeutic hepatocyte-growth factor levels that 
protected the animals from acute drug-induced liver failure. These important results 
demonstrate that genetically engineered cells containing theranostic gene 
circuits which dynamically interface with host metabolism could provide novel 
opportunities for preventing liver diseases. 
 
NON-ALCOHOLIC STEATOHEPATITIS 
Non-alcoholic liver disease: relationship with atherosclerosis and identification 
of novel mechanisms 
Whether steatosis is incidentally or causally associated with carotid atherosclerosis is 
a matter of intense debate. In this issue, Pais et al. conduced a large epidemiological 
study, including transversal and longitudinal cohorts, to address this question. In the 
transversal cohort, the authors found that steatosis predicted carotid intima-media 
thickness better than diabetes or dyslipidemia. In the longitudinal cohort (mean follow-
up 8±4 years), steatosis at baseline predicted carotid plaque occurrence, 
independent of classical cardiovascular risk factors. This important study demonstrates 
that in patients with metabolic syndrome at risk for cardiovascular events, steatosis 
contributes to early atherosclerosis. 
The development of novel targeted therapies for NAFLD is hampered by a poor 
knowledge of the cellular and molecular drivers. In this issue of the Journal, three 
studies have revealed important mechanisms of NAFLD that could represent new 
druggable targets for therapy. In the first study, Ntambi et al. demonstrated that 
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hepatic oleate, a monounsaturated fatty acid -MUFA-, regulates liver stress 
response partially through PGC-1α. MUFA are synthesized by the stearoyl-CoA 
desaturase (SCD) family of enzymes, during lipogenic dietary conditions. By using 
sophisticated dietary and genetic models in mice, the authors demonstrate an 
indispensable role of hepatic oleate in protection against lipogenic diet-induced hepatic 
injury, especially regarding the development on ER stress, and a crucial role for PGC-
1α in this biological effect. In the second study, Li et al. studied the role of tumor 
necrosis factor receptor-associated factor 5 (TRAF5) regulating hepatic steatosis. In 
this translational study, TRAF5 expression was decreased in the fatty livers of both 
NAFLD patients and obese mice, and in palmitate-treated hepatocytes. Loss and gain-
of-function studies in experimental models of NASH in mice demonstrated that TRAF5 
negatively regulates NASH and related metabolic dysfunctions by blocking 
JNK1 activity, which represents a potential therapeutic target for obesity-related 
metabolic disorders. In the third study, coming from the same Institution as the second 
one, Li et al studied the role of Dickkopf-3 (DKK3), a protein belonging to the DKK 
family, in NAFLD. DKK3 expression was significantly decreased in the livers of NAFLD 
patients and of obese mice as well as in cultured hepatocytes stimulated with palmitate. 
Further experimental approaches showed that DKK3 regulates insulin sensitivity 
and glucose tolerance as well as the inflammatory response in hepatocytes and 
in vivo. The mechanisms underlying this effect involve with ASK1 and p38/JNK 
pathway. All these mechanistic studies have identified pathways that regulate the 
development of NAFLD and other metabolic condition as a response of a lipogenic 
diet. 
 
GENETIC METABOLIC LIVER DISEASE 
Iron overload in Tyrosisemia Type 1 
In this issue, Bao et al. investigated disordered iron metabolism in a murine model of 
hereditary tyrosinemia type I (HT1), a disease of the tyrosine degradation pathway. 
The authors analyzed the status of iron accumulation in a murine model for HT1. 
Severe iron overload was observed in the murine model of HT1 with dramatically 
elevated hepatic and serum iron levels. Mechanistic studies revealed that 
downregulation and dysfunction of Tfr2 decreased hepcidin, leading to iron overload. 
Interestingly, low-iron food intake effectively reduced the iron deposits, protected the 
liver and prolonged the survival in these mice. This interesting study convincingly 
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demonstrates that iron was severely overloaded in the HT1 mice via the 
Sp1/Tfr2/Hepcidin axis. Maneuvers aimed at reducing iron accumulation could be 
potentially beneficial in patients with HT1. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
Deferring treatment increase HCV-associated liver-related mortality, assessing 
patient-reported outcomes (PROs), treating HCV in patients under hemodialysis 
Due to its high costs, treatment of chronic hepatitis C virus (HCV) infection is 
reimbursed in many countries only for those patients reaching advanced stages of 
disease. We do not know, however, if treatment can be safely deferred until advanced 
fibrosis stages without increasing the risk of liver-related complications. Zahnd et al. 
set out to estimate the impact of deferring HCV treatment on of liver-related 
complications in HIV/HCV co-infected individuals by using a model of liver disease 
progression and care with data from the Swiss HIV Cohort Study (SHCS) and the 
published literature. The percentage of individuals who died of liver-related 
complications increased from 2% if treatment was initiated in stage F0 or F1 to 
7%-22% if treatment was deferred until reaching fibrosis stages F3-F4. The 
strategy to defer treatment also significantly increased the time spent with replicating 
HCV. 
In line with these findings are the results of the study by Martin et al. who evaluated 
the optimal HCV treatment prioritization strategy for interferon-free HCV direct-acting 
antivirals by disease stage and risk status incorporating treatment of people who inject 
drugs (PWID). Their dynamic HCV transmission and progression model showed that 
treating PWID with moderate or mild disease with direct acting antivirals is cost-
effective compared to delay until cirrhosis. From a public health prevention strategy 
perspective both studies highlighting the need for scaling-up HCV treatment in order 
to reduce population-based liver-related mortality as well as HCV prevalence and 
transmission – which is likely to happen only once the costs of therapy are reduced. 
Treatment of chronic HCV infection may not only prevent hepatic disease progression 
but also improve patient-reported outcomes (PROs) such as health-related quality of 
life, fatigue, and work productivity, which have been shown to be significantly reduced 
in the HCV infected population. Younossi et al. assessed PROs with the new pan-
genotypic regimen - sofosbuvir plus velpatasvir - in 624 patients as compared to the 
placebo-treated group (n=116). Improvements in general health, emotional 
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wellbeing, and all domains of Chronic Liver Disease Questionnaire were 
observed already 4 weeks after starting treatment, and continued to improve at 
the end of therapy and thereafter. The greatest PRO benefits related to SVR were 
seen in those patients with substantially more pre-treatment PRO impairments. In 
contrast, the only PRO that improved in patients receiving placebo was the worry 
domain. This comprehensive and placebo-controlled analysis shows the impact on 
patients’ experience using validated instruments for assessment of patient-reported 
outcomes which is of significant importance when considering the effect of HCV 
treatment regimens. 
Sofosbuvir represents a backbone for many direct antiviral regimens but little is known 
about the use of sofosbuvir-containing regimens in end-stage renal disease. Desnoyer 
et al. described the pharmacokinetics, safety and efficacy of 400 mg sofosbuvir given 
either daily or three times a week in 12 HCV-infected patients requiring hemodialysis. 
Plasma concentrations of sofosbuvir or its inactive metabolite sofosbuvir-007 
did not accumulate with either regimen between hemodialysis sessions or 
throughout the treatment course. All patients receiving the daily regimen were cured, 
but two relapses occurred in the sofosbuvir three times daily group. Although the data 
speak for the safety and efficacy of the daily 400 mg sofosbuvir regimen in patients 
requiring hemodialysis, close clinical and drug monitoring especially for those having 
also advanced cirrhosis must be ensured until these findings are confirmed in larger 
trials. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
Hepatitis B core-related antigen (HBcrAg) as HCC predictor in low-risk patients 
Hepatitis B core-related antigen (HBcrAg) comprises HBV products of the precore/core 
gene and shares the first 149 amino acids of the hepatitis B core antigen. As serum 
HBcrAg may probably reflect transcriptional activity of the covalently closed circular 
HBV DNA (ccccDNA) it could be a useful novel biomarker for the prediction of disease 
activity, treatment response, and HCC development. In a large cohort of 1,031 patients 
with mild disease activity, and who were not treated with nucleos(t)ide analogues, Tada 
et al. analyzed HBV markers associated with the development of HCC. Independent 
predictors of HCC development were HBcrAg levels > 2.9 log U/mL and the presence 
of basal core promotor (BCP) mutations. HBcrAg was superior to HBV DNA also in 
predicting HCC risk throughout the follow-up period by time-dependent ROC 
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analysis. If confirmed by others, measuring HBcrAg may become an interesting tool 
to study HCC risk in low risk HBV-infected populations. 
 
CIRRHOSIS 
NGAL improves the prediction accuracy of the ACLF prognosis prediction 
models 
Acute on chronic liver failure (ACLF) is a newly defined syndrome that occurs in 
cirrhotic patients with acute deterioration requiring hospital admission. The diagnosis 
of the syndrome is made using the CLIF organ failure scoring system and the prognosis 
of patients is made using the CLIF ACLF score, which is an aggregation of readily 
available clinical and biochemical data. Ariza et al. use the data and samples from 
the CANONIC study and show that the addition of a measurement of urinary 
NGAL (neutrophil gelatinase-associated lipocalin), a marker of inflammation can 
significantly improve the performance of the currently available prognostic 
scores significantly. These exciting data could be translated into clinical practice with 
further independent validation. 
 
REGENERATION 
CAR is a central regulator of hepatic regeneration 
Recovery from liver resection is centrally dependent upon the ability of the liver to 
regenerate. The study from Tschuor et al. provides exciting new data describing the 
potential role of the nuclear receptor called nuclear receptor subfamily 1 group I 
member 3 (also known as constitutive androstane receptor, CAR; encoded by NR1I3) 
in mediating hepatic regeneration. Through many excellent investigations in 
appropriate models, they showed for the first time that the lack of appropriate 
CAR activity reduces the ability of the liver to regenerate following hepatectomy. 
They also show that using pharmacological strategies, enhancement of CAR could 
enhance hepatic regeneration providing a potential therapeutic target. The implications 
of this research to clinical practice could be enormous. 
 
